ARTICLE | Product Development
BCMA CAR Ts diverge in early lines, as Carvykti dominates market
In BioCentury’s latest Clinical Report, AbbVie hits in Parkinson’s, plus data from Shattuck, Merck and Celldex
October 1, 2024 11:20 PM UTC
A pair of BCMA CAR T cell announcements last week are refining the commercial landscape for the cell therapies in multiple myeloma, and despite a perpetual unmet demand, it’s becoming a winner-takes-most game.
On Wednesday, 2seventy bio Inc. (NASDAQ:TSVT) said it would discontinue enrollment in the Phase III KarMMa-9 study of Abecma idecabtagene vicleucel as first-line therapy in patients with a suboptimal response to autologous stem cell transplant. The company cited a shrinking population of patients eligible for the study due to improvements in standard of care...